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Abstract
Background: Hepatitis B virus (HBV) is a major cause of chronic liver diseases, and frequently results in hepatitis, cirrhosis,
and ultimately hepatocellular carcinoma. The role of HCV in associations with insulin signaling has been elucidated.
However, the pathogenesis of HBV-associated insulin signaling remains to be clearly characterized. Therefore, we have
attempted to determine the mechanisms underlying the HBV-associated impairment of insulin signaling.
Methodology: The expressions of insulin signaling components were investigated in HBx-transgenic mice, HBx-constitutive
expressing cells, and transiently HBx-transfected cells. Protein and gene expression was examined by Western blot,
immunohistochemistry, RT-PCR, and promoter assay. Protein-protein interaction was detected by coimmunoprecipitation.
Principal Findings: HBx induced a reduction in the expression of IRS1, and a potent proteasomal inhibitor blocked the
downregulation of IRS1. Additionally, HBx enhanced the expression of SOCS3 and induced IRS1 ubiquitination. Also, C/EBPa
and STAT3 were involved in the HBx-induced expression of SOCS3. HBx interfered with insulin signaling activation and
recovered the insulin-mediated downregulation of gluconeogenic genes.
Conclusions/Significance: These results provide direct experimental evidences for the contribution of HBx in the
impairment of insulin signaling.
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Introduction
An estimated 2 billion people worldwide are currently infected
with the hepatitis B virus (HBV), which results in chronic hepatitis,
cirrhosis, and in certain instances, hepatocellular carcinoma
(HCC) [1,2]. Among the four proteins originating from the
HBV genome, such as the polymerase, surface, core, and HBx
proteins, hepatitis B virus X, a small 154-amino acid protein, is a
multifunctional regulator which modulates a variety of host
processes via interaction with virus and host factors [3,4]. Previous
reports have demonstrated that HBx proteins induce the
expression of lipid synthesis-related genes and inflammation in
transgenic mice [5,6,7]. Generally, hepatic steatosis, the accumu-
lation of lipid in the hepatocytes, has negative effects on liver
functions, which may be resulted or caused by inflammation. NF-
kB is activated in the hepatocytes and cytokines including
interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-a), and
interleukin-1 beta (IL-1b) are overproduced in fatty liver. These
proinflammatory cytokines can participate in the attenuation of
insulin signaling [8,9,10].
Insulin signaling is mediated by a complex, highly integrated
network, which controls several processes. In the response of
insulin, insulin receptor (IR) phosphorylates insulin receptor
substrate (IRS) proteins, which are linked to the activation of
two main signaling pathways: the phosphatidylinositol 3-kinase
(PI3K)–Akt/protein kinase B (PKB) pathway, which is responsible
for the majority of the metabolic actions of insulin, and the Ras–
mitogen-activated protein kinase (MAPK) pathway, which regu-
lates the expression of some genes and cooperates with the PI3K
pathway to control cell growth and differentiation [11]. In the
liver, insulin is involved in a number of actions responsible for
glucose control and lipid metabolism. In relations with glucose
metabolism in liver, insulin regulates the glucose concentration by
inhibiting hepatic glucose production and stimulating glycogen
synthesis. On a molecular level, increased hepatic glucose
production is regulated by insulin, which can inhibit the expression
of key gluconeogenic enzymes, phosphoenolpyruvate carboxyki-
nase (PEPCK) and glucose-6-phosphatase (G6Pase) in normal
states. Also, insulin is a strong activator of the lipogenic pathway
through activation of lipogenic transcription factors, such as
SREBP-1 and ChREBP [12].
Suppressor of cytokine signaling (SOCS) proteins and cytokine-
inducible SRC homology 2 (SH2)-domain-containing (CIS)
proteins constitute a family of intracellular proteins that play
major roles in immune cell proliferation, differentiation, migra-
tion, and modulation of immune responses [13,14]. A mechanism
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proposed, which involved the activation of signal transducer
and activator of transcription 3 (STAT3) and the subsequent
induction of SOCS, a negative regulator of cytokine signaling
[15,16,17]. Activated STATs are translocated to the nucleus
where they bind to STAT response elements (SREs) on target
genes to regulate transcription. SOCS3 is a direct target of this
signaling cascade, and acts in a negative feedback loop to inhibit
STAT phosphorylation at the receptor complex [18]. In the
recent report, hepatic SOCS3 is a mediator of insulin resistance
in the liver; however, the hepatocyte-specific SOCS3-deficient
mice promote systemic insulin resistance by mimicking chronic
inflammation [19]. Generally, the induction of SOCS proteins
inhibits insulin signaling via several distinct mechanisms,
including direct interference with insulin receptor activation,
the blockage of IRS activation, and the induction of proteasome-
mediated IRS degradation [20,21].
Although recent evidence suggests that chronic hepatitis C is
associated with increased risk of development of insulin resistance
[22], the studies linking HBV to insulin resistance or diabetes
were less identified. However, some reports demonstrated their
relationship. Custro et al. examined that incidence of diabetes
mellitus in adults with CHB is four time higher than that in the
general population [23]. Also, patients with chronic hepatitis
have impaired glucose metabolism with hyperinsulinemia and
insulin resistance [24]. In another point of view, a report defined
that a high frequency of HBV infection is identified in diabetes
patients [25]. Based on previous studies, we hypothesize that
HBx-induced lipid accumulation and inflammation in the liver
can negatively effect on hepatic insulin signaling. In this study, we
have characterized the components of the insulin signaling
cascades in the context of HBx protein expression. Herein, we
demonstrate that the level of IRS1 is concomitantly downregu-
lated in HBx-expressing liver tissues and cells via the persistent
induction of SOCS3 proteins. We also examine that STAT3 is
activated in HBx protein expression and C/EBPa and STAT3
can increase the SOCS3 expression in the transcriptional level.
Furthermore, we present evidence suggesting that HBx interferes
with the activation of insulin signaling, thereby resulting in the
inhibition of the activities of insulin, including gluconeogenic
gene expression. This may clarify the molecular mechanisms by
which HBx expression is associated with the hepatic insulin
signaling.
Methods
Plasmids, reagents, and antibodies
pcDNA3/6myc/SOCS3 were a generous gift from Dr. Akihiko
Yoshimura [26]. pGL3B/SOCS3 promoter, pSUPER/GFP
control, and pSUPER/SOCS3 were generously provided by Dr.
Fred Schaper [27], HBV 1.2-mer wild-type and HBx null mutant
vectors derived from the HBV ayw subtype were kindly provided
by Dr. Wang-Shick Ryu [28,29]. m67-Luc construct (high-affinity
binding site for Stats followed by the luciferase gene) was kindly
provided from Dr. Jacqueline Bromberg [30]. pcDNA3/HA/HBx
derived from HBV adr subtype, pGL3B/PEPCK promoter, and
pCMX1/C/EBPa were previously described [6,31,32].
The transfection reagents PolyFect and JetPEI were purchased from
QIAGEN and Polyplus-transfection, respectively. All other reagents
were purchased from Sigma. The antibodies against IRS1 (sc-559),
Myc (sc-789), C/EBPa(sc-61), Akt1/2 (sc-8312), and SOCS3 (sc-9023)
were purchased from Santa Cruz Biotechnology, INC. and Actin
(A2066), HBx (MAB8419), HA (1 867 423), Phospho-Akt (Ser473)
(#9271), PI3K-p85 (#4292), Phospho-PI3K-p85 (Tyr458) (#4228),
STAT3 (#9132), Phospho-STAT3 (Tyr705) (#9131), Phospho-Tyr
(#9411), Phospho-IRS1 (Ser307) (07-247), and Insulin receptor b (07-
724) antibody were obtained from Sigma, Chemicon, Roche, Cell
Signaling, and Upstate, respectively.
Cell culture, transient transfection, and stable
transfection
HepG2 cell lines were maintained in DMEM-10% fetal bovine
serum (Gibco BRL). Transient transfections were conducted using
PolyFect or JetPEI reagents of cell cultures in 24-well culture plates
with the indicated reporter plasmids, then cotransfected with
mammalian expression vectors. Expression vectors were main-
tained at constant total amounts via the addition of empty vectors.
Relative luciferase activities were assessed by luciferin (BD
Biosciences). HepG2/HA and HepG2/HA/HBx stable transfec-
tants were as previously described [6,7], and maintained in
DMEM-10% FBS containing 200 mg/ml of G418.
RNA isolation, reverse transcriptase-polymerase chain
reaction, and quantitative real-time PCR
Total RNA from HepG2 cells was prepared using TRIzol
(Invitrogen) in accordance with the manufacturer’s recommenda-
tions. The cDNA was synthesized from 2 mg of total RNA with
Moloney murine leukemia virus (MMLV) Reverse Transcriptase
(Promega) with a random hexamer (Cosmo, Korea) at 37uC for
1 hour. A 1/25
th aliquot of the cDNA was subjected to PCR
amplification using gene-specific primers (Table 1). Real-time
PCR was performed with an SYBR Green I LightCycler-based
real-time PCR assay (Roche Applied Science). The reaction
mixtures were prepared using LightCycler Fast Start DNA master
mixture for SYBR Green I, 0.5 mM of each primer, 4 mM MgCl2.
All PCR conditions and primers optimized to produce a single
product of the correct base pair size.
Immunohistochemistry
The liver tissues of wild-type and HBx-transgenic mice derived
from the HBV adr subtype genome were kindly provided from Dr.
Je Kyung Seong. The production of HBx-transgenic mice has
already been reported [6,7,33]. The liver tissues were fixed in 4%
formaldehyde. In brief, the paraffin-embedded tissue sections were
deparaffinized and hydrated with distilled water. Immunohisto-
chemical staining was conducted using a DAB system (Zymed
Laboratories INC.) in accordance with the manufacturer’s
instructions. The anti-IRS1 and SOCS3 antibodies were diluted
to 1:100 with blocking buffer. As a negative control, the primary
antibody was replaced with normal immunoglobulin.
Chromatin immunoprecipitation assay
ChIP assays were conducted as described by the manufacturer
(Upstate Biotechnology, Lake Placid, NY) with some modifica-
tions. The chromatin solutions were sonicated and incubated with
anti-C/EBPa or control IgG, then rotated overnight at 4uC.
Chromatin DNA was purified and subjected to PCR analysis. In
order to amplify the human SOCS3 promoter regions harboring
C/EBPs binding sites, the following primer sets were utilized;
sense: 59-CTC GCG GCC CGC CCT CGG-39, antisense: 59-
GCT GCG TGC GGG GCC GAA GC-39. After amplification,
the PCR products were resolved on 1.5% agarose gel and
visualized via ethidium bromide staining.
Coimmunoprecipitation
The cells were lysed via the addition of radioimmunoprecipi-
tation assay (RIPA) buffer, then incubated for 10 minutes on ice
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centrifugation, an aliquot of the lysates was removed for Western
blotting, and the remainder was immunoprecipitated overnight
with 1.5 mg anti-C/EBPa, anti-HA, anti-STAT3, and anti-IRS1,
and 40 ml of protein G or A-Sepharose (50% suspension). Lysates
and immunoprecipitates were then separated via SDS-PAGE and
transferred onto PVDF membranes for blotting. The proteins were
detected using horseradish peroxidase-conjugated secondary
antibodies and visualized via chemiluminescence.
Statistical analysis
Statistical analyses were conducted via unpaired or paired t
tests, as appropriate. All data were expressed as the means 6 SD.
P values of ,0.05 were considered to be significant.
Results
HBx induces degradation of insulin receptor substrate 1
via the ubiquitin-proteasome pathway
In order to assess the effects of HBx on IRS1 in the liver, we
assessed the expression of IRS1 protein using immunoblotting and
immunohistochemistry, and determined that IRS1 was significantly
downregulated in the liver tissues of 9 and 15-month-old transgenic
mice (Figure 1A and 1C). The phosphorylation of Ser307 of IRS1,
which is located in the phosphotyrosine binding (PTB) domain, has
been correlated with negative regulation of insulin signalling
[11,34]. Its phosphorylation of IRS1 can inhibit insulin-stimulated
tyrosine phosphorylation of IRS1 and block interactions with the
insulin receptor and inhibit insulin action [35]. We noted that the
Ser307 phosphorylation levels of IRS1 proteins were higher in the
HBx-transgenic mice than in the controls, even though total IRS1
protein levels were reduced. However, protein expressions of IRb
werenotreduced.Wedetectednodifferences inthe mRNA levelsof
IRS1 of the transgenic mice in the RT-PCR (Figure 1A) and
quantitative real-time PCR (Figure 1B).
As shown in Figure 1D, western blot analysis consistently
demonstrated that the levels of IRS1 protein in three independent
HBx-stable transfectants were lower than in the parental cell lines.
We observed no differences in the mRNA levels of IRS1 in the
HBx-stable transfectants in RT-PCR (left) and quantitative real-
time PCR (right). We surmised that the expression level of the HBx
induced by a strong promoter in the transfection system is assured
to be greater than the physiological level expressed during chronic
HBV infection [7,28,36]. In consideration of this concern, we
assessed the effects of a modest level of HBx expression from a
HBV replicon, a greater-than-genome-length construct (1.2-mer).
As shown in Figure 1E, the transfection of the wild-type HBV 1.2-
mer (WT) in HepG2 cells resulted in the abrogation of IRS1
protein levels, whereas the transfection of the HBx-null mutant
(X
2) of HBV 1.2-mer did not reduce its expression as compared to
the wild-type. Furthermore, the ectopically expressed HBx could
recover the suppression of the HBx-null mutant (X
2) of HBV 1.2-
mer in IRS1 protein expression. The mRNA levels of IRS1 were
unchanged in the replicon-transfected cells. The transient
transfection of HBx into HepG2 cells induced a significant
suppression of protein levels of IRS1 in a dose-dependent manner.
However, a proteasome inhibitor, MG132, recovered the IRS1
protein level in HBx-transfected cells and mRNA levels of IRS1
were not changed (Figure 1F). We subsequently attempted to
determine whether IRS1 was ubiquitinated for protein degrada-
tion in HBx-transfected cells. HBx promoted the ubiquitination of
IRS1, particularly in the treatment of MG132 (Figure 1G). These
results support the notion that HBx can downregulate IRS1
proteins in both the liver of transgenic mice and hepatoma cell
lines expressing the HBx proteins.
HBx induces SOCS3 expression
Because previous reports have revealed a mechanism by which
the action of insulin is inhibited as the result of the increased
ubiquitination and degradation of IRS1 via SOCS1 and SOCS3
[20], we first evaluated the expression levels of SOCS1 and
SOCS3 proteins in the transgenic mice and HBx-transfected cells.
Although levels of SOCS1 protein and mRNA were not induced,
SOCS3 protein and mRNA levels were significantly higher in the
HBx-transgenic mice, particularly in the 9 and 15-month stages, as
compared to the control mice (Figure 2A and 2B). The results of
immunohistochemisty demonstrated that the levels of SOCS3
protein were induced in the 9 and 15-month-old transgenic mice
(Figure 2C). Furthermore, SOCS3 mRNA levels significantly
trended toward an increase in stable cells expressing the HBx
proteins, and these results were consistent with the protein level
observed in the immunoblotting results (Figure 2D). We then
evaluated the induction of SOCS3 mRNA and protein levels in
cells transiently transfected with HBx. As shown in Figure 2E, cells
transfected with HBx evidenced a statistically significant induction
of their mRNA levels as compared to control cells that were
Table 1. Primers for the RT-PCR amplification.
Gene Species Sense Antisense
IRS1 Human/Murine GGAGTACATG AAGATGGACC TGG CTGTTCGCAT GTCAGCATAG C
SOCS1 Human GAGAGCTTCG ACTGCCTCTT AGGTAGGAGG TGCGAGTTCA
SOCS3 Human TCCCCCCAGA AGAGCCTATT AC TACTGGTCCA GGAACTCCCG
SOCS3 Murine GCTGGCCAAA GAAATAACCA AGCTCACCAG CCTCATCTGT
C/EBPa Human GAGTGGCGGC AGCGGC CAGTTCGCGG CTCAGCTGTT
PEPCK Human CAGGCGGCTG AAGAAGTATG A CGTCAGCTCG ATGCCGATCT T
G6Pase Human GTGGATTCTC TTTGGACAGC G CAGACAGACA TTCAGCTGCA CA
HBx Human/Murine TTCTCATCTG CCGGTCCGTG GGGTCAATGT CCATGCCCCA
b-actin Human/Murine GACTACCTCA TGAAGATC GATCCACATC TGCTGGAA
GAPDH Human GTGGTCTCCT CTGACTTCAA TCTCTTCCTC TTGTGCTCTT G
GAPDH Murine CCATGTTTGT GATGGGTGTG AACC TGTGAGGGAG ATGCTCAGTG TTGG
doi:10.1371/journal.pone.0008649.t001
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also upregulated in the HBx-expressing cells. The mRNA
induction in quantitative real-time PCR was confirmed for
SOCS3 expression in stabley or transiently HBx expression cells
(Figure 2F). Taken together, these results suggest that the
expression of SOCS3 can be regulated by HBx proteins.
HBx enhances SOCS3-induced IRS1 protein degradation
As noted above, the SOCS3 proteins have been previously
reported to induce the proteasome-dependent degradation of
IRS1, and HBx may result in the induction of SOCS3 mRNA and
protein expression. In order to determine whether HBx-induced
SOCS3 expressions result in the reduction of IRS1 protein levels,
we cotransfected the SOCS3 expression vector into HBx-stable
cell lines. As shown in Figure 3A, the further downregulation of
IRS1 was observed in the coexpression of SOCS3 proteins.
Furthermore, we attempted to determine whether RNAi against
SOCS3 could markedly recover IRS1 protein levels (Figure 3B),
and the polyubiquitination of IRS1 was barely observed in the
coexpression of HBx and RNAi for SOCS3 (data not shown).
These data indicate that HBx promotes the SOCS3-mediated
downregulation of the IRS1 protein.
Figure 1. HBx decreases IRS1 expression. (A) The effects of HBx protein on IRS1 expression in wild-type and HBx-transgenic mice. Proteins in
liver extracts from control and HBx-transgenic mice were immunoblotted with anti-IRS1, anti-phospho-IRS1 (Ser307), anti-IRb, anti-HBx, and anti-Actin
antibodies. Total RNA was isolated from liver tissues, and the levels of IRS1, HBx, and b-actin mRNA were identified by RT-PCR. (B) The IRS1 mRNA
expression in wild-type and HBx-transgenic mice. Total RNA was extracted from liver tissues, and the levels of IRS1 mRNA were determined by
quantitative real-time PCR. The data were normalized relative to the GAPDH mRNA. (C) Left; Immunohistochemistry of IRS1 in livers of wild-type and
HBx-transgenic mice. Right; isotype controls of immunohistochemistry for IRS1 antibodies. (D) The effect of HBx protein on IRS1 expression in HepG2/
HA/HBx stable cells. HepG2 cell extracts stably transfected with HA-tagged HBx protein were immunoblotted with the IRS1 antibody. Total RNA was
also isolated from Mock or HBx stable cells and subjected to RT-PCR analysis (left) or quantitative real-time PCR (right) with primers for IRS1. (E) The
effect of the HBV replicon on IRS1 protein expression. HepG2 cells were transfected with the 1.2-mer replicon (a greater-than-genome-length)
construct, a wild-type (WT) or HBx-null mutant (X
2), and HBx. Total cell extracts were subjected to Western blot analysis with IRS1 antibodies and
total RNA was isolated from the replicon-transfected cells, and the levels of IRS1, HBx, and GAPDH mRNA were identified by RT-PCR (upper)o r
quantitative real-time PCR (bottom). The data were normalized relative to the GAPDH mRNA. (F) The effect of HBx on IRS1 protein expression in
HepG2 cells. HA-tagged HBx protein was transiently expressed for indicated concentrations in HepG2 cells. 48 hours after transfection, MG132
(25 mM) was added for 2 hours. Total RNA was isolated from the cells, and the levels of IRS1, HBx, and GAPDH mRNA were identified by RT-PCR
(upper) or quantitative real-time PCR (bottom). The data were normalized relative to the GAPDH mRNA. (G) The identification of ubiquitinated IRS1 by
HBx proteins. HA-tagged ubiquitin was expressed in Mock or HBx stable cells in the treatment of MG132, or not expressed. Whole-cell lysates were
immunoprecipitated with IRS1 antibodies and immunoblotted with HA antibodies.
doi:10.1371/journal.pone.0008649.g001
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Based on the data for increasing the mRNA levels of SOCS3 by
HBx, we further investigated the mechanisms for regulating
SOCS3 expression by HBx. We conducted a functional analysis of
the activation of the SOCS3 promoter. The structure of the
SOCS3 gene has been previously determined [37]. The putative
response elements present on the SOCS3 promoter are provided
in Figure 4A. Using the ‘MOTIF’ database analysis program to
identify any consensus sequences in the 59-flanking region of this
gene, we identified putative binding sites for several transcription
factors, including C/EBPs. Compared to the mock-transfected
cells, transfection with the HBx plasmid augmented the luciferase
activity of the SOCS3 promoter over two folds, indicating that the
induction of SOCS3 in response to HBx is mediated through the
transcriptional activation of the SOCS3 gene. In order to
investigate the possible involvement of transcription factors or
coactivators with HBx on this promoter, we cotransfected HBx
and transcription factors/coactivators, such as SREBP-1a,
SREBP-1c, C/EBPa, CBP, p300, and PGC-1a, into HepG2
cells. In particular, C/EBPa increased both the basal and HBx-
cotransfected luciferase expression of this promoter (Figure 4B).
Other transcriptional regulators did not induce the HBx-mediated
transactivation of the SOCS3 promoter (data not shown). ChIP
assays were conducted in order to further evaluate the binding of
C/EBPa to this promoter. C/EBPa bound on this promoter and
HBx expression increased its binding to the promoter (Figure 4C).
In order to assess the potential in vivo interaction between
endogenous C/EBPa and HBx proteins involved with SOCS3
expression, HepG2 cells were transfected with HA-tagged HBx
gene, and anti-C/EBPa immunoprecipitation was conducted,
followed by immunoblotting with anti-HA antibody. As shown in
Figure 4D, HBx proteins interacted with C/EBPa via anti-HA
antibody immunoprecipitation (left). And the interaction with HBx
and C/EBPa was also refined using anti-HA immunoprecipita-
tion, followed by Western blotting with antibody against C/EBPa
(right). These results suggest that the functional synergism of HBx
Figure 2. HBx increases SOCS3 expression. (A) The protein and mRNA expression of SOCS3 in wild-type and HBx-transgenic mice in a stage-
specific manner. The liver tissues of control mice and HBx homozygous transgenic mice were immunoblotted with anti-SOCS3 antibody. (B) The
SOCS3 mRNA expression in wild-type and HBx-transgenic mice. Total RNA was extracted from liver tissues, and the levels of SOCS3 mRNA were
determined by quantitative real-time PCR. The data were normalized relative to the GAPDH mRNA. (C) Left; Immunohistochemistry of SOCS3 in the
livers of wild-type and HBx-transgenic mice. Right; isotype controls of immunohistochemistry for SOCS3 antibodies. (D) The effect of HBx protein on
SOCS3 protein and mRNA expression in stable cell lines. HepG2 cell extracts stably expressing HA-tagged HBx protein were immunoblotted with the
SOCS3 antibody (left). Total RNA was also isolated from HBx-constitutive expressing cells and subjected to RT-PCR analysis with primers for SOCS3
(right). (E) The protein and mRNA expression of SOCS3 in transiently HBx-transfected cells. HA-tagged HBx were transiently expressed in HepG2 cells.
(F) The mRNA expression of SOCS3 in stable cells (left) or transiently HBx-transfected cells (right). The levels of SOCS3 mRNA were examined by
quantitative real-time PCR. The data were normalized relative to the GAPDH mRNA.
doi:10.1371/journal.pone.0008649.g002
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SOCS3 expression. Transfection of C/EBPa into HBx-expressed
stable cells induced a marked increase in the protein and the
mRNA levels of SOCS3 (Figure 4E, F). The mRNA induction in
quantitative real-time PCR was confirmed for SOCS3 expression
(Figure 4G).
In an effort to examine whether HBx performs a function in
SOCS3 gene expression by C/EBPa, we attempted to knockdown
of C/EBPa using specific siRNA for C/EBPa. As shown in
Figure 4H, siC/EBPa-transfected cells did not induce SOCS3
promoter activity, even in the transfection cells of HBx. Also, the
protein levels of SOCS3 were confirmed using Western blotting
(Figure 4I). The siC/EBPa-transfected cells did not augment the
protein expression of SOCS3 and the expression levels of IRS1
were increased noteworthily. As shown in Figure 4J and 4K, the
mRNA levels of SOCS3 in the RT-PCR and quantitative real-
time PCR was also not increased by HBx in the siC/EBPa-
transfected cells. These results showed that the association of C/
EBPa and HBx is required for the induction of SOCS3 expression
via the efficient recruitment of this promoter.
HBx-activated STAT3 is involved in SOCS3 expression
The tyrosine phosphorylation and activation of STATs results
in the upregulation of STAT target genes, including three families
of inhibitory proteins, the protein inhibitors of activated STATs
(PIAS), the SH2-containing phosphatase (SHP), and SOCSs
[38,39]. Also, previous reports have shown that HBx is capable
of activating STAT3 via some mechanisms [40,41]. We attempted
to determine whether HBx proteins were responsible for the
activation of STAT3 in our HBx-transgenic mice and cell lines,
given by the phosphorylation at Tyr705 [42,43]. The highest levels
of Tyr705 phosphorylation of STAT3 were detected in 15-month-
old HBx-transgenic mice (Figure 5A) and forced HBx expression
also increased STAT3 phosphorylation in the stable and transient
transfectants (Figures 5B and 5C). To further substantiate our
results, we examined whether HBx proteins promote activation of
STAT3 transcription factor. Transient transfection of the m67-
Luc construct, a reporter gene with STAT3 DNA binding sites
[30], into HepG2 cells with or without HBx was used to test
transcriptional activation by HBx-induced STAT3 phosphoryla-
tion. Upon induction of tyrosine phosphorylation of STAT3 by
HBx expression, transcriptional stimulation by wild type (WT)-
STAT3 became evident and a further increase transcription was
also achieved by constitutive active (CA)-STAT3 (STAT3-C,
which is dimerized by cysteine-cysteine residues instead of pY-SH2
interactions [30]) constructs). However, dominant negative (DN,
Tyr705 mutated with Phe) STAT3 significantly decreased the
HBx-induced STAT3 (WT or CA) activation (Figure 5D).
The immunoprecipitation of STAT3 and subsequent Western blot
analysis showed that the STAT3 interacted with HBx. Consistent
Figure 3. SOCS3 is required for HBx-induced IRS1 protein expression. (A) The degradation of IRS1 by cooperation between HBx and SOCS3.
Top; Mock and HBx-constitutively expressing HepG2 cells were transiently transfected with Myc-tagged SOCS3. 48 hours after transfection, the cell
extracts were immunoblotted with the IRS1-specific antibodies. Bottom; Image analysis of IRS1 protein expression by densitometry. (B) The effect of
HBx and SOCS3 siRNA on IRS1 protein expression. Top; Mock and HBx-constitutive expressing HepG2 cells were transiently transfected with pSUPER/
GFP control or pSUPER/SOCS3. The cell extracts were immunoblotted with the IRS1-specific antibodies. Bottom; Image analysis of IRS1 protein
expression by densitometry. Values were expressed as the means 6 SD. *P,0.05 and **P,0.01 compared with indicated controls.
doi:10.1371/journal.pone.0008649.g003
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HBx proteins, DN-STAT3 markedly disrupted the interaction of
these proteins (Figure 5E). This result suggests that the activation of
STAT3 by interaction with HBx proteins can induced the SOCS3
expression. Also, we subsequently detected the correlation between
C/EBPa and STAT3 with regard to the expression of SOCS3. As
shown in Figure 5F, the promoter activities of SOCS3 were higher in
the cotransfection of HBx, C/EBPa,and STAT3 (WTand CA). The
cotransfection of DN-STAT3 impaired the activation of the SOCS3
promoter. These results consistently indicate that HBx-induced C/
EBPa and STAT3 activation may be an upstream regulator of
SOCS3 expression.
HBx attenuates hepatic insulin signaling
In order to confirm that HBx-induced IRS1 downregulation
resulted in the impairment of insulin signaling, HBx-constitutive
expressing HepG2 cells were treated with insulin in concentrations
from 0 to 1000 nM for 1 hour, and the phosphorylation of p85
subunit of PI3K (Tyr458) and Akt (Ser473) were evaluated. The
insulin-induced phosphorylation of the p85 subunit of PI3K and
Figure 4. C/EBPa enhances HBx-induced SOCS3 expression. (A) Schematic representation of the transcriptional response elements on the
murine SOCS3 promoter, showing a distal SRE (295 to 287), a proximal SRE (271 to 264), an AP1 element (2105 to 299), a FoxO motif (2103 to
95), a GC-rich region (258 to 252), and a putative C/EBPs binding site (298 to 284). (B) The effects of HBx and C/EBPa on SOCS3 promoter activity.
HepG2 cells were transfected with SOCS3 reporter construct, HBx, and C/EBPa as indicated for 48 hr, after which the ratio of reporter activities was
utilized to measure the promoter activity of SOCS3. *P,0.0001 compared with C/EBPa transfectants. (C) ChIP analysis on the SOCS3 promoter. HepG2
cells were transfected with expression vectors for HBx and C/EBPa as indicated and harvested for ChIP analysis with anti-C/EBPa antibody, or control
IgG. The precipitated genomic fragments were amplified using primers flanking the C/EBPs binding sites on human SOCS3 promoters. Genomic DNA
from total chromatin lysates was included as an input control. The precipitates were confirmed using quantitative real-time PCR. (D) The interaction
between HBx and C/EBPa by coimmunoprecipitation. HA-tagged HBx was transiently expressed in HepG2 cells. Proteins in lysates were
immunoprecipitated (IP) and immunoblotted (IB) with the indicated antibodies. (E) The induction of SOCS3 protein expression by HBx and C/EBPa.
The C/EBPa protein was transiently expressed for 48 hr in Mock and stably HBx-transfected cells. Whole HepG2 cell extracts stably expressing HA-
tagged HBx protein were immunoblotted with the SOCS3-specific antibody. (F), (G) The mRNA expression of SOCS3 by HBx and C/EBPa in RT-PCR (F)
or quantitative real-time PCR (G). (H) The effect of C/EBPa knockdown on HBx-induced SOCS3 promoter activity. *P,0.0001 compared with the
indicated control. (I) The expression of SOCS3 proteins by HBx in the C/EBPa knockdown system. Whole cell lysates were immunoblotted with
indicated antibodies. (J). (K) The expression of SOCS3 mRNA by HBx in the C/EBPa knockdown system. Total RNA was extracted from the cells, and the
levels of SOCS3 mRNA were determined via RT-PCR (J) and quantitative real-time PCR (K).
doi:10.1371/journal.pone.0008649.g004
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even though the concentration of insulin was lower. However,
lower levels of the phosphorylation of these proteins were detected
in the HBx-expressing cells (Figure 6A). Total levels of PI3K-p85
and Akt remained unchanged by insulin treatment. We also
observed that HBx-transfected cells were induced a significant
decrease in the phosphorylation of p85 and Akt in response to
insulin treatment in the time-dependent manner, compared to
mock-transfeced cells (Figure 6B).
Furthermore, we assessed the tyrosine phosphorylation levels of
IRS1 immunoprecipitates in the stable transfectants of HBx genes.
Mostly, insulin-induced tyrosine phosphorylation of IRS1 can
positively regulate the insulin signaling, in opposition to phos-
phorylation on Ser307 (Figure 1A) [44]. As expected, the levels of
IRS1 tyrosine phosphorylation were reduced in the HBx-
expressing cells treated with insulin, as compared to the control
vector-transfected cells (Figure 6C).
HBx disrupts insulin-induced PEPCK and G6Pase
downregulation
Insulin reduces gluconeogenesis via the specific transcriptional
inhibition of PEPCK and G6Pase [45]. Thus, we attempted to
determine whether the attenuation of insulin signaling by HBx
disrupts the actions of insulin with regard to the suppression of
PEPCK and G6Pase expression. It was noted that the overex-
pression of HBx and SOCS3 proteins enhanced the promoter
activity of PEPCK and G6Pase (Figure 7A). Furthermore, as
shown in Figure 7B, although insulin attenuated the expression of
Figure 5. STAT3 activation is associated with HBx-induced SOCS3 expression. (A) The activation of STAT3 via HBx-induced tyrosine
phosphorylation. Proteins in liver extracts from control and HBx-transgenic mice were immunoblotted with anti-STAT3 and anti-phospho-STAT3
(Tyr705) antibodies. (B), (C) The effect of HBx protein on STAT3 phosphorylation in HepG2 cells. HepG2 cell extracts stably (B) and transiently (C)
transfected with HBx were immunoblotted with the STAT3 and phosphor-STAT3 (Tyr705) specific antibodies. (D) Transactivation of STAT3 by HBx
expression. The m67-Luc (150 ng) was cotransfected into HepG2 cell with the eukaryotic expression vectors for the wild type (WT), constitutive active
(CA), or dominant negative (DN) construct for STAT3 with or without HBx expression vectors. The luciferase activity was measured and the values are
expressed as the means 6 s.d. for at least four independent experiments. (E) The activation of STAT3 via interaction with HBx proteins. HA-tagged
HBx and dominant negative STAT3 constructs were transfected into HepG2 cells. Proteins in lysates were immunoprecipitated with anti-STAT3 and
immunoblotted with anti-STAT3 and anti-HA. (F) Luciferase activity of SOCS3 promoter dependent on the expression of HBx, C/EBPa, and STAT3 (WT,
CA, and/or DN). The values were expressed as the means 6 SD. *P,0.05 and **P,0.0001 compared with the indicated controls.
doi:10.1371/journal.pone.0008649.g005
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suppression of the promoter activity of these genes. We also
verified the mRNA levels of these genes in the RT-PCR and
quantitative real-time PCR (Figure 7C and 7D). Additionally, we
observed that RNAi against SOCS3 could not induce PEPCK and
G6Pase promoter activity in the presence of HBx (Figure 7E) and
confirmed the mRNA levels of PEPCK and G6Pase in the RT-
PCR (Figure 7F) and quantitative real-time PCR (Figure 7G).
Collectively, these results demonstrate that HBx induces decreased
insulin signaling, resulting in the inhibition of gluconeogenesis in
hepatocytes.
Discussion
As it has been estimated that approximately 53% of HCC cases
worldwide are associated with HBV, research into HBV infection
has been focused principally on the pathogenesis of HCC.
However, it is possible that the deregulation of a number of
metabolic components in HBV-infected livers may contribute to
the pathogenesis of advanced liver diseases. Among the four
proteins that originate from the HBV genome, such as
polymerase, surface, core, and HBx proteins, HBx is reported to
be associated with HBV-related pathogenesis [46]. Previous
Figure 6. HBx disturbs insulin signaling in hepatic cells. (A) The effect of HBx on the insulin-induced phosphorylation of the p85 subunit of
PI3K and Akt in the dose-response manner. Control and HBx-expressed stable cells were incubated in the presence of insulin for 60 minutes. Whole
cell lysates were subjected to immunoblotting for phosphor-p85 (Tyr458) and phosphor-Akt (Ser473). (B) The effect of HBs on the insulin-treated
phosphorylation of p85 and Akt in the time-course manner. Control and HBx stable cells were treated in the presence of 100 nM insulin for indicated
times. Total cell lysates were examined to Western blotting for phosphor-p85 (Tyr458) and phosphor-Akt (Ser473). (C) The effect of HBx on the
insulin-stimulated tyrosine phosphorylation of IRS1. Mock and HBx-expressed stable cells were treated for 60 minutes in the presence of 100 nM
insulin. From the total cell extracts, IRS1 proteins were immunoprecipitated (IP), corresponding with the anti-IRS1 antibody, followed by
immunoblotting with anti-phosphotyrosine antibody.
doi:10.1371/journal.pone.0008649.g006
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diseases via regulating of the expression of lipid synthesis-related
genes in transgenic mice and hepatic cells [5,6], and hepatic
inflammation is observed frequently in HBx-transgenic mice [6].
Some reports are demonstrated that patients with HBV infection
show an association between steatosis and insulin resistance, with
its clinical concomitants of obesity, hyperglycemia, and hypertri-
glyceridemia [47].
HBV should be considered to exert synergistic effects with
chronic inflammation [48]. Proinflammatory proteins, including
TNF-a, IL-6, and IL-1b, appear to participate in the induction
and maintenance of the subacute inflammatory state associated
with the accumulation of fat. We also noted that the mRNA levels
of TNF-a, IL-6, IL-1b, cyclooxygenase-2 (COX-2), C-reactive
protein (CRP), and matrix metalloproteinase-9 (MMP-9) expres-
sion were increased in the presence of HBx (data not shown).
Presumably, HBx-mediated fat accumulation may be associated
with the increased production of these cytokines in response to
viral hepatic infections or inflammation. Therefore, it could need
to identify the relationship with chronic HBV infection, inflam-
mation, and inflammation-related liver dysfunction, such as
disruption of insulin signaling. Collectively, based on the fact that
HBV, especially HBx proteins, induces hepatic steatosis and
inflammation, we examined the possible association with HBx and
insulin signaling.
The SOCS proteins are the most thoroughly studied inhibitors
of Jak/STAT signaling pathway and include 8 members (cytokine
inducible SH2 domain protein - CIS and SOCS 1 to 7), which are
expressed at low levels in unstimulated cells. After cell activation,
their expression increases, thereby inhibiting activated STATs
[13,26,49]. In this study, we showed that HBx-induced C/EBPa
and STAT3 activation was accompanied resulting in SOCS3
expressions were elevated. Also, given our observations that HBx
activates the STAT3-SOCS3 regulatory pathway via cooperation
with C/EBPa, the activation of this pathway is resulted in HBx-
induced IRS1 degradation. As IRS proteins constitute a critical
Figure 7. HBx suppresses insulin-inhibitory expression of gluconeogenic genes. (A) The promoter activity of PEPCK and G6Pase by HBx
and SOCS3. HepG2 cells were transfected with two promoters of PEPCK (left) and G6Pase (right) and expression vectors of HBx, and SOCS3. (B) The
inhibition of insulin-mediated promoter activity of PEPCK and G6Pase by HBx proteins. HepG2 cells were transiently transfected with PEPCK (left)o r
G6Pase (right) promoter construct and HBx in the presence or absence of insulin (100 nM). Luciferase assay was conducted to assess the promoter
activity of PEPCK and G6Pase, and the error bars represent the standard deviation. *P,0.05 and **P,0.005 compared with indicated controls. (C), (D)
Control and HBx stable cells were incubated for 1 h in the presence of insulin (100 nM). Total RNA was also isolated and subjected to RT-PCR analysis
(C) or quantitative real-time PCR (D) with primers for PEPCK and G6Pase. b-Actin or GAPDH expression served as a control. (E) The promoter activity of
PEPCK and G6Pase by HBx and RNAi against SOCS3 in the presence of insulin. HepG2 cells were transiently transfected with PEPCK (left) or G6Pase
(right) promoter construct and HBx and/or RNAi for SOCS3 in the presence of insulin (100 nM). Luciferase assay was conducted to assess the
promoter activity of PEPCK and G6Pase. (F), (G) The mRNA expression of PEPCK and G6Pase by HBx and/or siSOCS3 in treatments of insulin. Total RNA
was isolated and subjected to RT-PCR (F) or quantitative real-time PCR (G).
doi:10.1371/journal.pone.0008649.g007
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proteins in the liver may result in inhibition of insulin signaling
[50].
Compared with HCV infection, the association between HBV
infection, insulin signaling, and its complications have been less
clearly identified. The recent report was demonstrated that in
patients with HBV infection, the relationship between host
characteristics such as obesity and type 2 diabetes and HBV
infection was determined [47]. It was reported that obesity and
diabetes are predictors of HCC risk, possible depending on HBV
infection status [51]. In this study, we suggest the molecular
mechanisms resulting in the suppression of insulin signaling by
HBx proteins. However, future research may be required to
demonstrate the physiological significance of the disruption of
insulin signaling by HBV infection, especially HBx expression, and
host and/or external factors. Additionally, it is possible that HBx-
induced cellular stress, such as mitochondrial dysfunction,
oxidative stress, and endoplasmic reticulum stress, can be
associated with inhibition of insulin signaling. Studies might also
be necessary to explain a number of mechanisms, which can be
associated with liver dysfunctions.
In conclusion, our data indicate that HBx proteins are able to
augment SOCS3 expression and decrease IRS1 proteins, thereby
causing impairments of hepatic insulin signaling and inhibition of
hepatic insulin action. The results of the present study provide new
insight into the pathogenesis of HBV infection underlying the
deregulation of components of the insulin signaling framework and
chronic hepatic metabolic changes.
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